Cipla Sounds The Bugle On US Respiratory Ambition
Executive Summary
One "sizeable" respiratory inhalation launch in the US every year, starting next year, is what Cipla is targeting as it expands its global franchise in the segment, though a filing this year for generic Advair isn't likely. The Indian firm also expects to sew up multiple biosimilar deals targeted at key emerging markets.
You may also be interested in...
Cipla Bullish For Future, Caps Speculation On Top-Level Departures
After a tough Q3, Cipla indicates that things are looking up as it readies to enter fiscal 2020, with both the US and India businesses shaping up well. The company also sought to dispel concerns around top level exits.
Cipla Bullish For Future, Caps Speculation On Top-Level Departures
After a tough Q3, Cipla indicates that things are looking up as it readies to enter fiscal 2020, with both the US and India businesses shaping up well. The company also sought to dispel concerns around top level exits.
Cipla Warns Of Tough 2H - Pressure On Tender Business, Sanctions-Related Volatility
Cipla rang in a “modest” Q2 and management has cautioned that coming quarters might see significant headwinds including the impact of a constrained funding environment on the tender business and US sanctions-related turbulence in some markets.